Use of the NMF biomarker as predictive diagnostic for effective use of cyclosporine in the treatment of eczema

Project summary

Treatment of severe atopic dermatitis in children with systemic cyclosporine costs €7.000 per year. Improvement is seen in about 50% of patients. Objective diagnostic tools for effective use of cyclosporine are lacking, resulting in over- and undertreatment. This project will research if stratification of children with eczema/atopic dermatitis (AD) on the diagnostic biomarker tool improves efficient use of cyclosporine.
This project hypothesizes that cyclosporine will be more effective in children with moderate AD and low NMF biomarker and less effective in children with severe AD and normal NMF biomarker.